Zejula Leads to Fewer Side Effects Than Previously Reported, Real-world Study Suggests

Zejula Leads to Fewer Side Effects Than Previously Reported, Real-world Study Suggests
Ovarian cancer patients who receive Zejula (niraparib) after responding to platinum-based chemotherapy experience fewer adverse effects in a real-world setting than was reported in a Phase 3 clinical trial, a study found. However, the lower rate of side effects "may be due to the higher dosing in the trial study," researchers wrote. The study, "Real world occurrence of top three clinical-trial reported adverse events of PARP inhibitor niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer, a national retrospective observational study of a 200 mg/day starting-dose cohort," was presented last month at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany. Zejula, developed by Tesaro, is a PARP inhibitor indicated for the maintenance of ovarian cancer patients who are in a complete or partial response to platinum-based chemotherapy. The treatment was approved after positive data from the ENGOT-OV16/NOVA Phase 3 trial (
Subscribe or to access all post and page content.